Breast Cancer | Specialty

Value of Hereditary Breast Cancer Testing

May 31st 2016

Genetic Risk Assessment for Breast Cancer

May 31st 2016

Abemaciclib Active Against Multiple Tumor Types

May 30th 2016

Phase I trial results demonstrate that abemaciclib, a CDK 4/6 inhibitor, had significant clinical activity and an overall response rate of 31% in patients with hormone receptor-positive breast cancer.

Frontline Fulvestrant Bests Anastrozole in Advanced Breast Cancer

May 28th 2016

Frontline treatment with fulvestrant improved progression-free survival versus anastrozole for postmenopausal patients with locally-advanced or metastatic HR-positive breast cancer.

Role of Radiation Therapy Evolves for Elderly Patients With Breast Cancer

May 23rd 2016

Kevin Hughes, MD, discusses the pros and cons of radiation therapy in elderly patients with breast cancer, as well as luminal A patients, and the overall changing role of the treatment in the field.

Dr. Piccart on the MINDACT Study for Early-Stage Breast Cancer

May 19th 2016

Martine J. Piccart, MD, PhD, professor of Oncology, Université Libre de Bruxelles, director of Medicine, Jules Bordet Institute, Brussels, Belgium, discusses the primary analysis of the prospective randomized MINDACT study, which evaluated the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.

Novel CDK 4/6 Inhibitor Explored in Premenopausal Breast Cancer Setting

May 19th 2016

Researchers are exploring the safety and efficacy of the novel CDK 4/6 inhibitor ribociclib (LEE011) in the phase III MONALEESA- 7 trial.

Long-Term Data Uphold Neoadjuvant Pertuzumab Benefit in HER2+ Breast Cancer

May 19th 2016

A 5-year follow-up of the phase II NeoSphere trial confirmed that patients with HER2-positive breast cancer receiving a 3-drug neoadjuvant pertuzumab regimen had better outcomes compared with patients receiving trastuzumab and docetaxel.

Ribociclib Improves PFS in Phase III Breast Cancer Study

May 19th 2016

The combination of the CDK4/6 inhibitor ribociclib and letrozole significantly improved progression-free survival compared with letrozole alone for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Arnedos on the POP Randomized Trial for Early Breast Cancer

May 16th 2016

Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Dr. Ring on Molecular Profiling of CTCs in Advanced Breast Cancer

May 13th 2016

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.

Perou Shares How Deeper Sequencing of Genome Helps Define, Treat Breast Cancer Subtypes

April 28th 2016

Charles M. Perou, PhD, discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome, and how determining intrinsic subtypes can help guide breast cancer therapy.

Dr. Partridge on PGD in Young Patients With Breast Cancer

April 28th 2016

Ann H. Partridge, MD, MPH, founder and director, Program for Young Women with Breast Cancer, director, Adult Survivorship Program, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses preimplantation genetic diagnosis (PGD) in young patients with breast cancer.

Using Multiple Biomarkers Improves Risk Prediction for Breast Cancer

April 19th 2016

The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.

Frontline Palbociclib Extends PFS in Phase III Breast Cancer Study

April 19th 2016

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival for the frontline combination of palbociclib and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Neoadjuvant T-DM1 Plus Pertuzumab Shows Promise for HER2-Positive Breast Cancer

April 18th 2016

The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.

Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest Radiation

April 18th 2016

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood

Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer

April 18th 2016

Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.

70-Gene Signature Identifies Breast Cancer Subgroup Unlikely to Benefit From Adjuvant Chemo

April 18th 2016

A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.

Early-Stage Therapies Rapidly Evolving in Breast Cancer

April 13th 2016

Early intervention has increasingly become the new standard of care for many patients with breast cancer, with an ever-growing collection of phase III trials currently exploring several novel or improved approaches.